Sage May Be Forced To Simplify Brexanolone Dosing Regimen
Executive Summary
Advisory committee members warned of dosing errors and other potential problems with the titration/taper regimen used in the clinical trials, arguing a simpler dosing schedule also could increase patient access.
You may also be interested in...
Zulresso Postmarket Commitment Hints At Easier Dosing In Postpartum Depression
US FDA wants Sage Therapeutics to explore Zulresso use in alternative settings in a postmarketing trial. A successful study could expand access to the new approved brexanolone, whose administration is now long, complicated, and restricted to certified healthcare facilities.
Sage Gets More Time For Zulresso Launch Preparations With Delay Of US FDA Approval
After an advisory committee recommended approval for the postpartum depression treatment if administered under a REMS program at certified centers, Sage submitted a proposed REMS, causing the agency to extend the PDUFA date three months.
Sage's Brexanolone Could Be Transformative, But Only In Controlled Settings, US FDA Panel Says
Advisory committee strongly favored approval of postpartum depression therapy, but many members suggest it should be administered in a facility with trained medical staff to avoid potential safety concerns.